The Vanguard Group 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:00 pm Purchase |
2023-12-29 | 13G | BridgeBio Pharma, Inc. BBIO |
The Vanguard Group | 12,800,294 7.360% |
2,208,839 (+20.85%) |
Filing |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | BridgeBio Pharma, Inc. BBIO |
The Vanguard Group | 10,591,455 7.090% |
1,259,772 (+13.50%) |
Filing |
| 2022-02-09 3:33 pm Purchase |
2021-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
The Vanguard Group | 9,331,683 6.340% |
2,890,371 (+44.87%) |
Filing |
| 2021-02-10 10:39 am Purchase |
2020-12-31 | 13G | BridgeBio Pharma, Inc. BBIO |
The Vanguard Group | 6,441,312 5.250% |
6,441,312 (New Position) |
Filing |